Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Stem Cell Transplant for Hemoglobinopathies
NCT00034528Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2001
- Primary completion
- Nov 2003
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine in sickle cell anemia (SCA), beta thalassemia major, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2001; status: terminated.
02
Drugs
busulfanfludarabine
03
Conditions
sickle cell anemia (SCA)beta thalassemia major
Beyond the preview
Go deeper on NCT00034528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034528.